Cargando…

A phase I study of pazopanib in combination with escalating doses of (131)I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine

OBJECTIVE: This trial was conducted to evaluate the ability of pazopanib to overcome therapeutic (131)I resistance. MATERIALS, METHODS AND PATIENTS: This phase 1 trial assesses the combination of pazopanib and escalating doses of radioiodine ((131)I) in patients with recurrent or metastatic thyroid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chow, Laura Q., Santana-Davila, Rafael, Pantel, Austin, Roth, Mara, Anderson, Leslie N., Failor, Alan, Doot, Robert, Mankoff, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490965/ https://www.ncbi.nlm.nih.gov/pubmed/28662033 http://dx.doi.org/10.1371/journal.pone.0178325

Ejemplares similares

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Radioiodination and Purification of [(131)I]β-CIT and [(131)I]FP-CIT with an Automated Radiosynthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2022)

Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of (131)I during radioiodine therapy of Graves’ disease
por: Happel, C., et al.
Publicado: (2021)

Treatment failure in hyperthyroid cats after radioiodine (I‐131) injection
por: Mullowney, Deirdre, et al.
Publicado: (2021)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Improving (131)I Radioiodine Therapy By Hybrid Polymer-Grafted Gold Nanoparticles
por: Le Goas, Marine, et al.
Publicado: (2019)

Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
por: Elsaidi, Hassan, et al.
Publicado: (2019)

Apoptosis gene reprograming of human peripheral blood mononuclear cells induced by radioiodine-131 ((131)I) irradiation
por: Li, Jian-Fang, et al.
Publicado: (2019)

Adverse Reactions to Radioiodine 131I Therapy of Goiter in West African Tertiary Hospital
por: Onimode, Yetunde A., et al.
Publicado: (2016)

Predictors of euthyreosis in hyperthyroid patients treated with radioiodine (131)I(−): a retrospective study
por: Stachura, Albert, et al.
Publicado: (2020)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
por: Mester, Alexandru, et al.
Publicado: (2020)

Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions
por: Pantel, Austin R., et al.
Publicado: (2022)

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
por: Gao, Haiyan, et al.
Publicado: (2023)

The false-positive radioiodine I-131 uptake in the foreign body granuloma located in gluteal adipose tissue
por: Gültekin, Salih Sinan, et al.
Publicado: (2011)

Radioiodine Accumulation in a Giant Ovarian Cystadenofibroma Detected Incidentally by 131-I Whole Body Scans
por: Mebarki, Mohammed, et al.
Publicado: (2012)

Radioiodine ((131)I) therapy in a child with autism spectrum disorder: A complex and demanding task
por: Bibbo, Giovanni, et al.
Publicado: (2019)

Radioiodine Contamination Artifacts and Unusual Patterns of Accumulation in Whole-body I-131 Imaging: A Case Series
por: Ozcan Kara, Pelin, et al.
Publicado: (2014)

Autonomous Functioning Thyroid Nodule in a 4-year-old Male Child Treated with Radioiodine (I-131)
por: Khare, Abhishek, et al.
Publicado: (2013)

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial
por: De Wolf, Katrien, et al.
Publicado: (2017)

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
por: Diéras, Véronique, et al.
Publicado: (2016)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
por: Négrier, Sylvie, et al.
Publicado: (2017)

Effects of drugs on the efficacy of radioiodine ((131)|) therapy in hyperthyroid patients
por: Oszukowska, Lidia, et al.
Publicado: (2010)

Ultrasonography Echotexture as a surrogate for Sialadenitis secondary to 131I Radioiodine Therapy for differentiated Thyroid Cancer: a review and metaanalysis
por: Lima, Graziele Aparecida Simões, et al.
Publicado: (2020)

Thyroid Cancer after Exposure to Radioiodine in Childhood and Adolescence: (131)I-Related Risk and the Role of Selected Host and Environmental Factors
por: Zupunski, Ljubica, et al.
Publicado: (2019)

MON-443 SPECT/CT Localization of Incidental Diverticular Bleed After Radioiodine (i(131)) Therapy for Metastatic Thyroid Cancer
por: Doshi, Sejal B, et al.
Publicado: (2020)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Ultrasound-guided implantation of radioactive (125)I seed in radioiodine refractory differentiated thyroid carcinoma
por: Chen, Wei, et al.
Publicado: (2021)

Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.
por: Kemshead, J. T., et al.
Publicado: (1998)

The influence of thyroid hormone medication on intra-therapeutic half-life of (131)I during radioiodine therapy of solitary toxic thyroid nodules
por: Happel, Christian, et al.
Publicado: (2022)

Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated (131)I therapy?
por: Jiang, Yongji, et al.
Publicado: (2023)

A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism
por: Doi, Suhail AR, et al.
Publicado: (2001)

A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

(131)I–Tositumomab in lymphoma
por: Cheung, M.C., et al.
Publicado: (2009)

Nontoxic Goiter (NTG) and Radioiodine: What Do Patients Think About It? Quality of Life in Patients with NTG Before and After 131-I Therapy
por: Kaniuka-Jakubowska, Sonia, et al.
Publicado: (2018)

Primary autoimmune thrombocytopenia and co-existing Graves’ disease: Role of radioiodine-131
por: Jung, Rayamajhi Sampanna, et al.
Publicado: (2014)

Radiosensitive effect of curcumin on thyroid cancer cell death induced by radioiodine-131
por: Hosseinimehr, Seyed Jalal, et al.
Publicado: (2014)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma
por: Lee, Su Jin, et al.
Publicado: (2014)

Strong Neck Accumulation of (131)I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone
por: Enomoto, Keisuke, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fqvh1eqr9nliahnomq2sbqjqnq